Kriya Medical Technologies, a leading medical devices company headquartered in Chennai, has received its manufacturing license from the Central Drugs Standard Control Organization (CDSCO) for its product KRIVIDA Trivus Respi Panel RT-qPCR Kit, a first of its kind kit that has the unique capability to simultaneously identify Respiratory Syncytial Virus (RSV), Influenza viruses and SARS-CoV-2 in patients presenting with respiratory tract infections.
KRIVIDA Trivus Respi Panel RT-qPCR kit has been validated by ICMR- National Institute of Virology, Pune, and the kit has shown 100% specificity and 99.11% sensitivity for the detection of all three viruses.
A key feature of this kit is its ability to detect RSV, a virus that primarily causes viral pneumonia in children under the age of 5 and contributes significantly to hospitalizations. Additionally, RSV is a common cause of lower respiratory tract diseases (LRTD) in older adults, potentially leading to life-threatening pneumonia and bronchiolitis. Hence, early detection of RSV is imperative for both infants and the elderly.
In India, influenza accounts for 35% of all respiratory tract infections. In severe cases, the progression from influenza-like illness (ILI) to acute lung injury and acute respiratory distress syndrome can be rapid, resulting in high mortality rates. The Krivida Trivus Respi Panel RT-qPCR Kit helps in early detection of influenza, thereby enabling the prompt initiation of specific antiviral medications.
The kit can also detect co-infections, which are associated with increased disease severity, morbidity, and mortality due to a weakened immune system. The Krivida Trivus Respi Panel RT-qPCR Kit is a valuable tool for improving diagnostic and infection control capacity.
